Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

nt with Janssen, total amounts in excess of the annual cap ("Excess Amounts") plus interest may not exceed $225 million.

The Company has recognized the Excess Amounts as a reduction to operating expenses in the current year as the Company's repayment of the Excess Amounts to Janssen is contingent and would become payable only after the third profitable calendar quarter for the product under the collaboration. Further, the Excess Amounts shall be reimbursable only from the Company's share of future full calendar quarter pre-tax profits (if any) after the third profitable calendar quarter for the product under the collaboration.

For the calendar year ended December 31, 2012, the Company's total share of collaboration expenses under the Agreement was $68.1 million. As of December 31, 2012, total Excess Amounts totaled $18.1 million, of which during the quarter ended December 31, 2012, $17.3 million was recorded as a reduction to research and development expense and $0.8 million was recorded as a reduction to general and administrative expense.

GAAP operating expenses were $40.6 million for the six months ended December 31, 2012, compared to $30.6 million for the six months ended December 31, 2011. Included in operating expenses for the six months ended December 31, 2012 is the $18.1 million reduction to operating expenses for Excess Amounts.

GAAP operating expenses were $16.7 million for the quarter ended December 31, 2012, compared to $16.0 million for the quarter ended December 31, 2011 and $23.9 million for the quarter ended September 30, 2012. Included in operating expenses for the quarter ended December 31, 2012 is the $18.1 million reduction to operating expenses for the Excess Amounts.

At December 31, 2012, the Company had cash, cash equivalents and marketable securities of $317.1 million, compared with $203.6 million at June 30, 2012. In addition, as of December 31, 2012, the Company had $26.6 million receivable from Jansse
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... , Feb. 26, 2015 The healthcare landscape ... ever-changing arena, Frost & Sullivan will host its 20 ... Executive MindXchange , March 8 to 10, at the Hilton ... Calif. This event is a platform ... leaders to discuss industry disruptions and how to succeed in ...
(Date:2/26/2015)... RURO, Inc., a leading LIMS, RFID and sample ... latest update to the bestselling commercial-off-the-shelf sample management system. ... and easy method to gain better control of sample ... has enhanced the system’s support for those customers who ... records. , "FreezerPro has become the go-to system ...
(Date:2/26/2015)... LOS ANGELES , Feb. 26, 2015 ... diversified life sciences company with interests in the natural ... platform technology, announced today that its products will be ... upcoming Roth Capital Partners, 27 th Annual Growth ... Ritz Carlton, located at 1 Ritz Carlton Drive, ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 On Wednesday, ... to building a nationwide Clostridium difficile (C. diff) awareness ... diff burden study by the Centers for Disease Control ... caused almost half a million infections among Americans in ... nursing homes. , The study also estimates that ...
Breaking Biology Technology:Embrace the Future of Medical Technologies with Frost & Sullivan 2Embrace the Future of Medical Technologies with Frost & Sullivan 3RURO Releases FreezerPro® version 6.2 2SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 2SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 3SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 4Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 2Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 3Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 4
... Inc. (Nasdaq: CEPH ) today reported second quarter ... compared to net sales of $712.4 million for the second ... period was $1.54 compared to $1.18 for the second quarter ... net income for the second quarter of 2011 was $142.6 ...
... Hair-growth developer Divine Skin Inc. (DSKX) introduced a new molecule, ... scalp and surpass minoxidil for efficacy and tolerability. The innovative ... its molecular weight is lower than that of minoxidil, a ... "This is a significant step forward in topical therapy, ...
... Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today reported financial ... 30, 2011. For the second quarter of 2011, ... per basic and diluted share, compared to a net income ... diluted share, respectively, in the same period of 2010. Basic ...
Cached Biology Technology:Cephalon Reported Financial Results for the Second Quarter of 2011 2Cephalon Reported Financial Results for the Second Quarter of 2011 3Cephalon Reported Financial Results for the Second Quarter of 2011 4Cephalon Reported Financial Results for the Second Quarter of 2011 5Cephalon Reported Financial Results for the Second Quarter of 2011 6Cephalon Reported Financial Results for the Second Quarter of 2011 7Cephalon Reported Financial Results for the Second Quarter of 2011 8Cephalon Reported Financial Results for the Second Quarter of 2011 9Cephalon Reported Financial Results for the Second Quarter of 2011 10Cephalon Reported Financial Results for the Second Quarter of 2011 11Cephalon Reported Financial Results for the Second Quarter of 2011 12Biotech Developer Divine Skin (DSKX) Debuts New Hair-Growth Molecule Nanoxidil 2Rigel Announces Second Quarter 2011 Financial Results 2Rigel Announces Second Quarter 2011 Financial Results 3Rigel Announces Second Quarter 2011 Financial Results 4Rigel Announces Second Quarter 2011 Financial Results 5
(Date:2/25/2015)... 2015  ABC Financial Services (ABC), the leading ... and Fitness Industry, today announced enhancements to their ... latest upgrade includes advances to the agreement section ... via Identity One fingerprint biometrics. The features will ... displays at the International Health, Racquet & Sportsclub ...
(Date:2/24/2015)... NEW YORK , Feb. 24, 2015 This ... Thousands. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... America . Annual estimates and forecasts are provided for ... is provided for these markets. Market data and analytics are ...
(Date:2/24/2015)... -- This report analyzes the worldwide markets for Face and Voice ... Voice Biometrics. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Latin America . Annual estimates and forecasts are ... analysis is provided for these markets. Market data and analytics are ...
Breaking Biology News(10 mins):ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16
... DUBLIN , April 4, 2013 ... ) has announced the addition of the ... Three, Four & Five-Factor], Application & Geography ... their offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ...
... University of Leeds may have solved a key puzzle about ... While it is generally accepted that some important ingredients ... have not been able to explain how that inanimate rock ... study shows how a chemical, similar to one now found ...
... lives in the United States each year, according to ... crusade against cancer recently achieved a victory under the ... Hawthorne. Hawthorne,s team has developed a new form of ... mice. This innovative treatment produced none of the harmful ...
Cached Biology News:Research and Markets Announces the Release of 'Multi-Factor Authentication Market - by Model/Type [Two, Three, Four & Five-Factor], Application & Geography - Forecasts (2012 - 2017)' 2Research and Markets Announces the Release of 'Multi-Factor Authentication Market - by Model/Type [Two, Three, Four & Five-Factor], Application & Geography - Forecasts (2012 - 2017)' 3Power behind primordial soup discovered 2Power behind primordial soup discovered 3Breakthrough cancer-killing treatment has no side-effects 2
... Protein Phosphatase ( l-PPase) ... phosphatase with activity towards ... tyrosine residues. It is ... of the ORF221 open ...
... Monitoring Kit measures adenosine triphosphate ... and a dynamic range. Based ... assay measures ATP in bacterial, ... a concentration range of 10-11 ...
Immulon 2HB, Flat Bottom, 50/Bx; high binding irradiated surface to provide increased binding affinity for hydrophilic proteins and complexes....
Thermo Forma provides an array of accessory Racks for the Cryo/CryoPlus 16" Diameter storage system. To maximise inventory capacity a Jumbo Arrowhead configuration is recommended. You may choose betw...
Biology Products: